RDGLOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

VIVOS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.05−0.00 (-2.51%)

Close on Oct 19, 2026

Market cap: $23.44M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2013 Ended Dec 31, 2013	Jan 16, 2014	After market close	–	–	–

Press releases

Announcements Vivos filed with the SEC

Feb 10, 2025, 3:37 PM ET
Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Other events · EX-99.1 to Form 8-K
Jul 1, 2024, 9:29 AM ET
Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Other events · EX-99.1 to Form 8-K
Oct 11, 2023, 6:33 AM ET
provisional patent on the chiller and related equipment expires on 12/30/23 so we authorized Indiano Law Group to file for a utility
Other events · EX-99.1 to Form 8-K
Jan 27, 2022, 4:35 PM ET
Inc. Provides 2021 Recap and Outlines 2022 Objectives
Other events · EX-99.1 to Form 8-K

Where these numbers come from

Parsed from the XBRL in Vivos's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-8 reverse split on Aug 13, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDGL.

Revenue growth91.5% · median -49.3%

Gross margin-25.9% · median -76.8%

Operating margin-2852.5% · median -2157.4%

Net margin-3633.6% · median -2157.4%

Company	Revenue	Growth
PETV	$1.18M	-9.5%
PAVM	$112.00K	-89.0%
RDGL	$99.10K	+91.5%
GIPL	$30.00K	–
GUTS	–	–
PFSA	–	–

Company

Exchange: OTC
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 1
Auditor: Fruci & Associates II, PLLC
SEC CIK: 1449349

Advertisement
300 × 250